CN1682723A - 氢溴酸东莨菪碱鼻用干粉吸入剂及制备方法 - Google Patents
氢溴酸东莨菪碱鼻用干粉吸入剂及制备方法 Download PDFInfo
- Publication number
- CN1682723A CN1682723A CN 200510033328 CN200510033328A CN1682723A CN 1682723 A CN1682723 A CN 1682723A CN 200510033328 CN200510033328 CN 200510033328 CN 200510033328 A CN200510033328 A CN 200510033328A CN 1682723 A CN1682723 A CN 1682723A
- Authority
- CN
- China
- Prior art keywords
- scopolamine hydrobromide
- dry powder
- binding agent
- nose
- powder inhalant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000843 powder Substances 0.000 title claims abstract description 51
- 229960004499 scopolamine hydrobromide Drugs 0.000 title claims description 68
- WTGQALLALWYDJH-MOUKNHLCSA-N scopolamine hydrobromide (anhydrous) Chemical compound Br.C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 WTGQALLALWYDJH-MOUKNHLCSA-N 0.000 title claims 17
- 238000000034 method Methods 0.000 title description 18
- 238000002360 preparation method Methods 0.000 claims abstract description 31
- 239000003085 diluting agent Substances 0.000 claims abstract description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 7
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 35
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 35
- 239000011230 binding agent Substances 0.000 claims description 33
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 33
- 229960003943 hypromellose Drugs 0.000 claims description 33
- 239000003795 chemical substances by application Substances 0.000 claims description 25
- 239000002671 adjuvant Substances 0.000 claims description 24
- 239000000227 bioadhesive Substances 0.000 claims description 23
- 229920000642 polymer Polymers 0.000 claims description 22
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 19
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 14
- 239000008101 lactose Substances 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 14
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 13
- 238000011049 filling Methods 0.000 claims description 13
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 13
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 13
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 13
- 239000008187 granular material Substances 0.000 claims description 9
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 8
- 239000002245 particle Substances 0.000 claims description 8
- 238000005303 weighing Methods 0.000 claims description 8
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 7
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 7
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 7
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 239000007779 soft material Substances 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 20
- 201000003152 motion sickness Diseases 0.000 abstract description 9
- 238000012856 packing Methods 0.000 abstract description 5
- 238000002156 mixing Methods 0.000 abstract description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 abstract description 3
- 238000007873 sieving Methods 0.000 abstract 3
- 230000001464 adherent effect Effects 0.000 abstract 1
- 239000000853 adhesive Substances 0.000 abstract 1
- 230000001070 adhesive effect Effects 0.000 abstract 1
- 239000003364 biologic glue Substances 0.000 abstract 1
- LACQPOBCQQPVIT-SEYKEWMNSA-N scopolamine hydrobromide trihydrate Chemical compound O.O.O.Br.C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 LACQPOBCQQPVIT-SEYKEWMNSA-N 0.000 description 52
- 210000001331 nose Anatomy 0.000 description 25
- 239000000126 substance Substances 0.000 description 17
- 239000000243 solution Substances 0.000 description 15
- 210000003928 nasal cavity Anatomy 0.000 description 13
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 12
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 11
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 229960002646 scopolamine Drugs 0.000 description 11
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 238000010521 absorption reaction Methods 0.000 description 9
- 210000002850 nasal mucosa Anatomy 0.000 description 9
- 238000003556 assay Methods 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 238000005070 sampling Methods 0.000 description 7
- 210000004877 mucosa Anatomy 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000007689 inspection Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 4
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- 230000001886 ciliary effect Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000005286 illumination Methods 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 235000010603 pastilles Nutrition 0.000 description 3
- 229940098458 powder spray Drugs 0.000 description 3
- 238000004088 simulation Methods 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 229930003347 Atropine Natural products 0.000 description 2
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- BNPSSFBOAGDEEL-UHFFFAOYSA-N albuterol sulfate Chemical compound OS(O)(=O)=O.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 BNPSSFBOAGDEEL-UHFFFAOYSA-N 0.000 description 2
- 229960000396 atropine Drugs 0.000 description 2
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000004081 cilia Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 231100000021 irritant Toxicity 0.000 description 2
- 210000003254 palate Anatomy 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 229960003712 propranolol Drugs 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- 210000001213 vestibule labyrinth Anatomy 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 241000269417 Bufo Species 0.000 description 1
- 102000009660 Cholinergic Receptors Human genes 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 240000007175 Datura inoxia Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000007964 Organophosphate Poisoning Diseases 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 241000208292 Solanaceae Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000005030 aluminium foil Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 210000003027 ear inner Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N ferric oxide Chemical compound O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- -1 hydroxypropyl Chemical group 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000013332 literature search Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229940079977 phenobarbital 30 mg Drugs 0.000 description 1
- WRLGYAWRGXKSKG-UHFFFAOYSA-M phenobarbital sodium Chemical compound [Na+].C=1C=CC=CC=1C1(CC)C(=O)NC([O-])=NC1=O WRLGYAWRGXKSKG-UHFFFAOYSA-M 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 238000013094 purity test Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940125725 tranquilizer Drugs 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 150000004684 trihydrates Chemical class 0.000 description 1
- JACRWUWPXAESPB-UHFFFAOYSA-M tropate Chemical compound OCC(C([O-])=O)C1=CC=CC=C1 JACRWUWPXAESPB-UHFFFAOYSA-M 0.000 description 1
- 210000001944 turbinate Anatomy 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
辅 料 | 浓度 | 摆动时间(min) | 恢复情况 | |
生物粘附剂 | HPMC | 0.5% | 60~70 | 立即恢复 |
CMC-Na | 1% | 90~100 | 立即恢复 | |
Carbopol 940 | (卡波姆)2% | ~15 | 不可恢复 | |
海藻酸钠 | 0.5% | 35~40 | 30min后恢复 | |
分散稀释剂 | 乳糖 | 5% | 60~70 | 立即恢复 |
微晶纤维素 | 5% | 5 | / | |
阳性对照 | 普奈洛尔 | 1% | 15 | 不可恢复 |
阴性对照 | 生理盐水 | 0.9% | 3~4小时 | / |
样品号 | 中间体主药含量(/25mg) | |
方法1(μg) | 方法2(μg) | |
1 | 200.0 | 199.3 |
2 | 194.7 | 202.4 |
3 | 206.9 | 200.7 |
4 | 202.2 | 201.4 |
X±SD | 200.9±5.06 | 201.0±1.29 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100333284A CN100493501C (zh) | 2005-02-25 | 2005-02-25 | 氢溴酸东莨菪碱鼻用干粉吸入剂及制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100333284A CN100493501C (zh) | 2005-02-25 | 2005-02-25 | 氢溴酸东莨菪碱鼻用干粉吸入剂及制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1682723A true CN1682723A (zh) | 2005-10-19 |
CN100493501C CN100493501C (zh) | 2009-06-03 |
Family
ID=35262343
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005100333284A Active CN100493501C (zh) | 2005-02-25 | 2005-02-25 | 氢溴酸东莨菪碱鼻用干粉吸入剂及制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100493501C (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102652740A (zh) * | 2011-12-17 | 2012-09-05 | 东莞达信生物技术有限公司 | 一种富马酸卢帕他定干粉吸入剂及其制备方法 |
CN108358911A (zh) * | 2018-04-19 | 2018-08-03 | 安徽德信佳生物医药有限公司 | 一种磁性诱导结晶分离东莨菪碱的方法 |
-
2005
- 2005-02-25 CN CNB2005100333284A patent/CN100493501C/zh active Active
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102652740A (zh) * | 2011-12-17 | 2012-09-05 | 东莞达信生物技术有限公司 | 一种富马酸卢帕他定干粉吸入剂及其制备方法 |
CN108358911A (zh) * | 2018-04-19 | 2018-08-03 | 安徽德信佳生物医药有限公司 | 一种磁性诱导结晶分离东莨菪碱的方法 |
Also Published As
Publication number | Publication date |
---|---|
CN100493501C (zh) | 2009-06-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1053339C (zh) | 受控释放***制剂 | |
CN1682723A (zh) | 氢溴酸东莨菪碱鼻用干粉吸入剂及制备方法 | |
CN1225464C (zh) | 汉黄芩素的提取工艺、药用组合物及制剂制备工艺 | |
CN1899587A (zh) | 治疗肩周炎、关节炎等症的贴剂及其制备方法 | |
CN1698873A (zh) | 一种心力丸口腔崩解片及其制备方法 | |
CN1270712C (zh) | 非洛地平控释制剂 | |
CN1443535A (zh) | 马来酸替加色罗口服制剂及其制备工艺——治疗肠易惹综合征 | |
CN1850202A (zh) | 一种***外用药物组合物及其制备方法和用途 | |
CN1250228C (zh) | 三七总皂苷口腔崩解片及其制备方法 | |
CN1582952A (zh) | 积雪草总苷在制备防治心、脑血管疾病药物中的用途 | |
CN1733109A (zh) | 治疗冠心病的软胶囊及其制备方法 | |
CN1857385A (zh) | 一种治疗颈椎病的药物组合物及其制备方法 | |
CN1891256A (zh) | 一种冠心丹参分散片及其制备方法 | |
CN1660413A (zh) | 干扰素含片在制备治疗复发性口腔溃疡药物中的新用途 | |
CN1810242A (zh) | 长春西汀缓释胶囊及其制备方法 | |
CN1268327C (zh) | 布洛芬精氨酸伪麻黄碱复方制剂 | |
CN1813685A (zh) | 一种增强匹多莫德对酸碱稳定性的包衣颗粒、其生产方法及其应用 | |
CN101062040A (zh) | 稳定型葫芦素液体组方及其制剂 | |
CN1389208A (zh) | 苯二氮卓类药物口服脉冲释药***及其制备方法 | |
CN101066252A (zh) | 氨基葡萄糖钙片制剂及其制备方法 | |
CN101036681A (zh) | 铁棒锤止痛回药 | |
CN1273137C (zh) | 布洛芬精氨酸可待因复方制剂 | |
CN1245980C (zh) | 一种治疗抑郁症的口服缓、控释制剂 | |
CN1891265A (zh) | 一种参附口腔崩解片及其制备方法 | |
CN1947733A (zh) | 一种肿节风软胶囊制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Jiaxuan Medicine Science and Technology Development Co., Ltd., Shenzhen City Assignor: Ding Guohua Contract record no.: 2010440000496 Denomination of invention: Scopolamine hydrobromide dry powder inhalant for nose and preparing method Granted publication date: 20090603 License type: Exclusive License Open date: 20051019 Record date: 20100517 |
|
TR01 | Transfer of patent right |
Effective date of registration: 20181211 Address after: 518000 One of the Seventh Floors of Southwest Real Estate Building at the Junction of Nigang Road and Bagua Road, Futian District, Shenzhen City, Guangdong Province (Office Only) Patentee after: SHENZHEN HUIMIN PHARMACEUTICAL CO., LTD. Address before: 518000 Guohua Building, Qiaoxiang Road, Futian District, Shenzhen City, Guangdong Province 7F Patentee before: Ding Guohua |
|
TR01 | Transfer of patent right |